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Abstract
Background:  In cancer cells, telomerase induction helps maintain telomere length and thereby bypasses
senescence and provides enhanced replicative potential. Chemical inhibitors of telomerase have been shown to
reactivate telomere shortening and cause replicative senescence and apoptotic cell death of tumor cells while
having little or no effect on normal diploid cells.
Results: We designed siRNAs against two different regions of telomerase gene and evaluated their effect on
telomere length, proliferative potential, and gene expression in Barrett's adenocarcinoma SEG-1 cells. The
mixture of siRNAs in nanomolar concentrations caused a loss of telomerase activity that appeared as early as day
1 and was essentially complete at day 3. Inhibition of telomerase activity was associated with marked reduction
in median telomere length and complete loss of detectable telomeres in more than 50% of the treated cells.
Telomere loss caused senescence in 40% and apoptosis in 86% of the treated cells. These responses appeared to
be associated with activation of DNA sensor HR23B and subsequent activation of p53 homolog p73 and p63 and
E2F1. Changes in these gene regulators were probably the source of observed up-regulation of cell cycle
inhibitors, p16 and GADD45. Elevated transcript levels of FasL, Fas and caspase 8 that activate death receptors
and CARD 9 that interacts with Bcl10 and NFKB to enhance mitochondrial translocation and activation of caspase
9 were also observed.
Conclusion: These studies show that telomerase siRNAs can cause effective suppression of telomerase and
telomere shortening leading to both cell cycle arrest and apoptosis via mechanisms that include up-regulation of
several genes involved in cell cycle arrest and apoptosis. Telomerase siRNAs may therefore be strong candidates
for highly selective therapy for chemoprevention and treatment of Barrett's adenocarcinoma.
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Background
Senescence and apoptosis normally counteract cancer
development and ability of cancer cells to disrupt these
processes is 'lifeline' of cancer [1]. Oncogenes such as ras
and myc can not induce oncogenesis unless intracellular
mediators of senescence and apoptosis are disrupted.
Most anticancer agents act by stimulating intracellular
mechanisms for cellular senescence and apoptosis; they
do not simply destroy them directly. The ability of these
drugs to reactivate the normal or activate alternate intrac-
ellular signals for replicative senescence and apoptosis in
cancer cell determines the sensitivity and efficacy of the
anticancer drugs [1].
One of the mechanisms by which cancer cells bypass nor-
mal cellular senescence is the elevated expression of the
enzyme telomerase that replicates telomeric DNA [2]. Tel-
omeres are tandem repeats of six-nucleotide sequence
(TTAGGG) that protect the ends of chromosomes from
being recognized as damaged DNA. Normally, during cell
division telomeres shorten because DNA polymerase that
replicates all DNA, is unable to copy telomeric DNA distal
to the site of last primase. In normal somatic cells telom-
eres progressively shorten as 50–100 base pair telomeric
DNA is lost with each round of cell division. When the tel-
omeres reach critical shortening, DNA damage is sensed
by DNA sensing molecules that activate intracellular proc-
esses that lead to irreversible cell cycle arrest and replica-
tive senescence [3]. The replicative senescence limits the
potential of somatic cells for population doubling and
hence limits their growth [4].
Telomere length can be preserved by an enzyme, telomer-
ase. Telomerase contains a catalytic unit with reverse tran-
scriptase activity (hTERT) and an RNA part that provides
template for telomere extension [2]. Telomerase is nor-
mally expressed only in stem cells such as those found in
hematopoeitic tissues, gastrointestinal and skin epithe-
lium and germ-line cells but is nearly absent in most
somatic cells [5]. However, approximately 90% of cancers
express high levels of telomerase activity [5]. Induction of
telomerase activity bypasses normal cellular senesce in
cancer cells and endows them with unlimited replicative
potential which is one of the key features of all cancer
cells. Suppression of telomerase activity in cancer cells
may reactivate telomere shortening. However, such tel-
omere shortening may be more acute and may lead to
acutely inducible form of cellular senescence [1]. Suppres-
sion of telomerase activity has also been reported to cause
apoptosis of cancer cells. Although, normally, senescent
cells may be resistant to apoptosis, chemical inhibitors of
telomerase have been shown to cause replicative senes-
cence as well as apoptosis in cancer cells [6-8].
Signaling pathways involved in reactivation of senescence
and apoptosis associated with telomerase inhibition in
cancer cells are not fully understood. The signaling mole-
cule, p53, that mediates cell cycle arrest and apoptosis in
normal ageing is also considered important in inducing
cell cycle arrest following telomere shortening. However it
may be genetically or otherwise deleted or rendered inef-
fective in cancer cells. Recently two P53-related genes, P73
and P63 (also known as p73alphaL, p63alpha, p40, TP51,
KET and AIS) with striking sequence homology to P53
have been identified [9]. The actions and regulation of
p73 and p63 and their isoforms are complex and their tar-
gets may be different than those of p53. In the past it was
generally believed that cellular stress and DNA damage
induce only p53. However it has now been shown that
p73α is the mediator of p53-independent, DNA damage
induced, cell cycle arrest and apotosis [9,10]. DNA dam-
age associated with telomerase shortening may also acti-
vate other signaling pathways that lead to cell cycle arrest
and apoptosis.
Several approaches have been proposed to achieve telom-
erase suppression. These approaches include: anti-sense
oligonucleotides, targeting RNA component of telomer-
ase [7], chemical inhibitors of telomerase [11], small mol-
ecule pharmaceuticals that target hTERT [12], and
telomerase vaccine [13]. Chemical inhibitors of telomer-
ase may also exert side effect whereas molecular antago-
nism such as with siRNAs should produce selective
suppression of telomerase, however, the effectiveness or
feasibility of this approach has not been reported.
Esophageal adenocarcinoma arises from specialized intes-
tinal metaplasia of the Barrett's esophagus which is a com-
plication of gastro-esophageal reflux disease [14].
Esophageal adeno-carcinoma has a rapidly rising inci-
dence, poor response to chemotherapy and overall poor
survival rate [15]. In development of this cancer, intestinal
metaplasia gradually progresses through different stages
of dysplasia to invasive adenocarcinoma [14]. Telomerase
activity is elevated in the metaplastic cells [16] and is fur-
ther elevated in the adenocarcinoma [7,16]. Therefore, tel-
omerase inhibition may have potential in treatment and
chemprevention of esophageal adenocarcinoma.
The purpose of the present studies in Barrett's associated
adenocarcinoma SEG-1 cells was: 1) to examine the feasi-
bility and effectiveness of telomerase siRNAs to inhibit tel-
omerase; 2) to examine whether selective telomerase
inhibition leads to senescence and apoptosis; and 3) to
identify signaling pathways of telomerase inhibition
induced senescence and apoptosis in cancer cells.
We found that telomerase siRNAs targeted against two
regions of the human telomerase, caused efficientMolecular Cancer 2005, 4:24 http://www.molecular-cancer.com/content/4/1/24
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inhibition of telomerase expression, loss of telomerase
activity and severe telomere shortening. Telomere short-
ening was associated with senescence and apoptotic cell
death. Gene expression studies revealed that telomerase
inhibition was associated with elevated expression of p73,
p63, and E2F1. Elevated transcript levels of genes mediat-
ing cell cycle arrest such as p21, p16 and GADD45 and
those implicated in apoptosis such as FasL, Fas, caspase 8,
proapototic CARD 9, caspases 7 and 3 were also observed.
Results
SiRNA uptake and loss of telomerase expression
Cy-3 labeled control RNA duplex (Dharmacon) at 50 nM
was introduced into cells using different transfection rea-
gents and methods. Delivery of siRNA by TransIT-TKO
reagent (Mirus) resulted in the best transfection efficiency
81 ± 3% (data not shown). Amount of siRNA delivered
per cell was also considerably higher following transfec-
tion with this reagent.
Utilizing TransIT TKO transfection reagent (Mirus, Madi-
son, WI), telomerase specific and control (siControl;
Dharmacon) siRNAs were introduced into SEG-1 cells.
On day 7, the transfected cells were evaluated for telomer-
ase protein by immunofluorescence and western blot
analyses. For immunofluorescence, the cytospins of trans-
fected cells were fixed and incubated with rabbit polyclo-
nal antibody to telomerase. Antigen-antibody complex
was detected by incubation with a fluorescein isothiocy-
anate (FITC)-labeled secondary antibody. Telomerase
expression, seen as green fluorescence in SEG-1 cells
treated with control siRNA (Figure 1A, panel II), is not
detected in cells treated with telomerase specific Tel-siR-
NAs (Figure 1A; panel IV). SiRNA mediated inhibition of
telomerase expression was also confirmed by western blot
analysis using a polyclonal anti-telomerase antibody.
Consistent with immunofluorescence, the expression of
telomerase in cells transfected with Tel-siRNAs was
reduced 95% relative to the cells treated with control siR-
NAs (Figure 1B and 1C).
SiRNA mediated inhibition of telomerase activity
BEAC cells (SEG-1) were treated with telomerase specific
(Tel) siRNAs for different durations, using TransIT-TKO
reagent. Telomerase activity was assessed using TRAPEZER
XL Telomerase Detection Kit which provides a highly sen-
sitive, quantitative, and non-isotopic version of the origi-
nal TRAP (Telomeric Repeat Amplification Protocol)
assay. The kit utilizes "Fluorescence Energy Transfer"
primers to generate fluorescently labeled TRAP products
which can be quantitated by a fluorescence plate reader.
The modifications of primer sequence and internal PCR
control added in this assay allow a more accurate quanti-
tation of telomerase activity in vitro. Telomerase activity
was assessed in lysates (1000 cell-equivalents) of SEG-1
cells treated with control or Tel-siRNAs. Telomerase activ-
ity in cells transfected with Tel-siRNAs was reduced 77 ±
3%, as early as day 1 (Figure 1D). A complete inhibition
of telomerase activity was observed in these cells at day 3.
Control siRNA had no effect on telomerase activity in
SEG-1 cells (Figure 1D).
Inhibition of SEG-1 cell growth
SEG-1 cells were transfected weekly with control or telom-
erase-specific siRNAs and substrate-attached viable cell
number was counted. A marked inhibition of cell prolifer-
ation was observed in SEG-1 cells in all three treatments
with Tel-siRNAs. Viable cell number did not change for
the first seven days, and then gradually declined by 77–
85% by 28 days (Figure 2A). Exposure of normal
(CRL7820) cells to siRNA for four weeks had no effect on
cell viability (Figure 2B).
Telomere shortening by telomerase siRNAs
We next analyzed telomere length following exposure of
SEG-1 cells to telomerase specific siRNAs, for 3 weeks. The
effect of telomerase inhibition on telomere length of indi-
vidual chromosomes was evaluated by Telomere-FISH
(Figure 3A, B, and 3C). Telomeres could be seen as red
dots at the ends of almost all chromosomes, in cells
treated with control siRNA (Figure 3A). However in cells
treated with telomerase siRNAs, 60% chromosomes
appeared to have telomere-free ends, indicating complete
erosion of telomeric ends on these chromosomes (Figure
3B and 3C). "Telomere length", the mean size of telomeric
restriction fragments generated by digesting the DNA with
telomere-sparing restriction endonucleases was also esti-
mated using genomic DNA isolated for each cell sample
[17]. Consistent with Telomere-Fish data, the exposure of
SEG-1 cells to telomerase specific siRNAs for 3 weeks, led
to a marked (1000 bp) reduction in median telomere
length (Figure 3D).
siRNA mediated telomerase inhibition leads to senescence
SEG-1 cells treated with siRNAs for three weeks were har-
vested and analyzed for senescence associated β-galactos-
idase expression, as described above. Senescence, as
indicated by β-galactosidase staining (blue colour), was
detected in 41 ± 6% cells transfected with Tel-siRNAs (Fig-
ure 4A, panel II). A subset of telomerase siRNA treated
SEG-1 cells also showed typical senescent morphology
(Figure 4A; panel III). Senescent cells were not seen in
SEG-1 cells treated with control siRNAs (Figure 4A; panel
I) or in non-cancer cells treated with control or telomerase
specific (Tel) siRNAs (Figure 4B).
Induction of apoptosis following siRNA treatments
SEG-1 cells treated with control or telomerase specific siR-
NAs for three weeks were evaluated for annexin V labe-
ling, a marker for early apoptosis. Cells treated with Tel-Molecular Cancer 2005, 4:24 http://www.molecular-cancer.com/content/4/1/24
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Effect of telomerase-specific siRNAs on telomerase expression and activity in SEG-1 cells Figure 1
Effect of telomerase-specific siRNAs on telomerase expression and activity in SEG-1 cells. (A). Control (Cont) or 
telomerase specific (Tel) SiRNAs were transfected into Barrett's associated adenocarcinoma cells (SEG-1) and the cells were 
analyzed for protein levels of telomerase at day 7 by immunostaining, using a rabbit polyclonal antibody against telomerase. 
Antigen-antibody complex was located by incubation of cells with FITC-labeled anti-rabbit secondary antibody. Transfected 
cells within the same microscopic field were viewed and photographed by phase contrast (PC) or by fluorescence emitted at 
518 nm (FITC filter). Using the FITC filter, telomerase positive cells appear bright green. (B). SEG-1 cells were treated exactly 
as described for panel "A" and telomerase expression was monitored by western blot analysis using a rabbit polyclonal anti-tel-
omerase antibody. (C). Bar graph showing relative expression of telomerase in control (Cont) or telomerase (Tel) siRNA 
treated SEG-1 cells, as assessed by western blot analysis (shown in panel B). (D). SEG-1 cells were transfected with control 
(Cont) or telomerase specific (Tel) SiRNAs and evaluated for telomerase activity at days 1, 3, and 5 after transfection. Telom-
erase activity was evaluated using TRAPEZER XL Telomerase Detection Kit, a highly sensitive, quantitative, and non-isotopic 
version of the original Telomeric Repeat Amplification Protocol. Briefly the cell lysates (1000 cell-equivalents) were mixed with 
TRAPEZER XL reaction mix containing Amplifuor™ primers, incubated for 30 min at 30°C, and telomerase products generated 
by PCR were quantitated using a Fluorescence Plate Reader. Telomerase activity in SEG-1 cells treated with control siRNAs 
for 5 days and the cells treated with telomerase specific siRNAs for days 1, 3, and 5, is shown in TPG (total product generated) 
units.
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siRNAs led to > 80% cells in apoptosis, as detected by
annexin V staining (Figure 5A, panel V). Less than 2% cells
were labeled with annexin in untreated SEG-1 samples.
The siRNA treated cells were also evaluated for poly(ADP-
ribose) polymerase (PARP), a protein which undergoes
caspase-3 mediated cleavage into 89- and 24-kDa
fragments during apoptosis. As shown in Figure 5 (panels
B and C), the PARP was mostly intact in control siRNA
treated cells with only 2% cleaved, as indicated by appear-
ance of 89 kDa fragment (Figures 5B and 5C). However in
the cells treated with telomerase specific (Tel) siRNAs, a
major fraction (55%) of PARP appeared as cleaved (89
kDa) fragment thus confirming the induction of apopto-
sis following telomerase inhibition.
Limited replicative potential of BEAC cells treated with telomerase specific SiRNAs Figure 2
Limited replicative potential of BEAC cells treated with telomerase specific SiRNAs. Barrett's associated adeno-
carcinoma cells SEG-1 (A) or normal cells from stomach and intestine (CRL7869) (B) were transfected with control (◆ ) or 
telomerase specific (▲ ) siRNAs and cultured for four weeks. At the end of each 7-day treatment cycle, cells were harvested 
and the number of viable cells was determined using trypan blue exclusion.
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Effect of telomerase inhibition on gene expression profile
SEG-1 cells were transfected with telomerase specific (Tel)
siRNAs. After 2 weeks, the cells were harvested, total RNA
isolated, and gene expression profile was analyzed using
U133 arrays (Affymetrix) representing 33,000 human
genes, as described previously [7]. Gene expression values
of independently conducted experiments showed excel-
lent correlation (R2 0.98; not shown). SiRNA treatment
resulted in a ≥2-fold change in 600 out of 33,000 genes
surveyed. Changes in some of the known genes involved
in DNA damage sensing, cell cycle arrest and apoptosis are
shown (see Additional file 1). Telomere shortening fol-
lowing siRNA mediated telomerase suppression produced
a ≥2-fold up-regulation of genes for DNA damage recogni-
tion and DNA repair protein HR23B; p53 family proteins
p73 and p63 and their regulators, E2F1 and MDM2; cell
Reduction in telomere length following siRNA treatment of BEAC cells Figure 3
Reduction in telomere length following siRNA treatment of BEAC cells. SEG-1 cells were transfected with control 
or telomerase specific siRNAs and telomere length was analyzed either by fluorescent in situ hybridization of metaphase chro-
mosomes, using the Cy3-PNA (C3TA2)3 probe (A, B, C) or by southern hybridization of genomic DNA to a telomere-specific 
probe (D). (A) SEG-1 cells were treated with control siRNAs for 3 weeks and telomeres on individual chromosomes were 
analyzed using Telomere-FISH, as described. Telomeres shown as red dots can be seen on most, if not all chromosomes. (B) 
SEG-1 cells were treated with telomerase specific (Tel) siRNAs for 3 weeks and telomeres were analyzed using Telomere-
FISH. Majority of chromosomes are without any telomeres (absence of red dots). The chromosomes which have telomeres 
(red dots), have a relatively weaker signal, indicative of shorter telomeres; (C) Bar graph showing number of telomeres (red 
dots) found per 5 cells analyzed at random. (D) SEG-1 cells, transfected with control (Cont) or telomerase specific (Tel) siR-
NAs, were cultured for 3 weeks. Genomic DNA was isolated and median telomere length was determined by southern hybrid-
ization, as described. Median Telomere Length (TL) for each treatment is indicated by arrows.
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cycle inhibitors p21, p16 and GADD 45; and pro-apop-
totic proteins, FasL, Fas, and CARD9. There was also a 1.5
fold increase in the gene expression of caspase 8, caspase
7, and caspase 3. A subset of expression changes were also
confirmed by western blot analysis (Figure 6). Consistent
with gene expression data, protein products of p63, FASL,
and p16 were also elevated = 2-fold in SEG-1 cells treated
with telomerase siRNAs relative to those treated with con-
Senescence following treatment of SEG-1 cells with telomerase specific siRNAs Figure 4
Senescence following treatment of SEG-1 cells with telomerase specific siRNAs. SEG-1 cells were transfected with 
either control or telomerase specific siRNAs and cultured for three weeks. For senescence assay, cells were rinsed in PBS and 
stained overnight in solution containing X-gal. Expression of β-galactosidase was monitored using an Olympus® fluorescence 
microscope. Panels: A I. SEG-1 cells transfected with control siRNA, evaluated for of β-galactosidase expression. A II. SEG-1 
cells transfected with telomerase siRNA, evaluated for of β-galactosidase expression. Expression of β-galactosidase is seen as 
blue colour. A III. Typical senescence associated morphology in a subset of SEG-1 cells transfected with telomerase siRNAs. B 
I. Normal cells from stomach and intestine, transfected with control siRNA and evaluated for of β-galactosidase expression. B 
II. Normal cells from stomach and intestine, transfected with telomerase specific siRNAs and evaluated for of β-galactosidase 
expression.
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Apoptosis following treatment of BEAC cells with telomerase siRNAs Figure 5
Apoptosis following treatment of BEAC cells with telomerase siRNAs. SEG-1 cells, transfected with control (Cont) 
or telomerase specific (Tel) siRNAs were cultured for three weeks and analyzed for apoptosis by evaluating annexin labeling or 
cleavage of PARP. A. Cells were mixed with annexin V-BIOTIN and treated sequentially with streptavidin conjugated to fluo-
rescein isothiocyanate (FITC) and propidium iodide (PI). Apoptotic cells within the same microscopic field were viewed and 
photographed by phase contrast (PC) or by fluorescence emitted at 518 nm (FITC filter). Using the FITC filter, early apop-
totic cells (positive for Annexin V-Biotin-FITC staining) appear bright green. B. SEG-1 cells were treated exactly as described 
for panel A and analysed for cleavage of poly(ADP-ribose) polymerase (PARP), a marker for apoptosis. PARP was identified by 
western blotting using a rabbit polyclonal antibody against PARP (Santa Cruz). C. Bar graph showing percentage of PARP found 
to be cleaved in cells treated with control or telomerase siRNAs.
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trol siRNAs. Although not detected by gene expression
profiling, western blot analysis also indicated a marked
upregulation of tumor necrosis factor (ligand) super-
family, member 10 (TRAIL) (Figure 6), a protein which
specifically induces apoptosis in transformed and tumor
cells, but not in normal cells.
Discussion
This study shows that in Barrett's adenocarcinoma SEG 1
cells, siRNAs targeting human telomerase can be effi-
ciently delivered and results in a rapid inhibition of tel-
omerase activity. The inhibition of telomerase activity is
associated with: 1) a complete erosion of telomeres of
Induction of apoptosis proteins following treatment of SEG-1 cells to telomerase specific siRNAs Figure 6
Induction of apoptosis proteins following treatment of SEG-1 cells to telomerase specific siRNAs. SEG-1 cells, 
transfected with control (Cont) or telomerase specific (Tel) siRNAs were cultured for two weeks and analyzed for protein 
expression by western blotting. The expression of p63, TNF-related apoptosis inducing ligand (TRAIL), TNF ligand superfamily, 
member 6 (FASL), and p16 was monitored using mouse monoclonal anti-p63 (Zymed), rabbit polyclonal anti-TRAIL (Santa 
Cruz), mouse monoclonal anti-FASL (Cell Science), and mouse monoclonal anti-p16 (Sigma) antibodies, respectively. A. West-
ern blot showing expression of p63 and TRAIL in control (Cont) and telomerase (Tel) siRNA treated cells. B. Bar graph show-
ing relative expression of p63 and TRAIL following normalization with glyceraldehyde-3-phosphate dehydrogenase (GAPDH). 
C. Western blot showing expression of FASL and p16 in control (Cont) and telomerase (Tel) siRNA treated cells. D. Bar 
graph showing relative expression of FASL and p16 following normalization with glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH).
GAPDH
TRAIL
P63
CONT TEL
GAPDH
P18
FASL
CONT TEL
0
1
2
3
4
5
0
0.5
1
1.5
2
2.5
3
3.5
4
R
e
l
a
t
i
v
e
 
E
x
p
r
e
s
s
i
o
n
O
f
 
F
A
S
L
P
r
o
t
e
i
n
R
e
l
a
t
i
v
e
 
E
x
p
r
e
s
s
i
o
n
O
f
 
P
1
8
P
r
o
t
e
i
n
Cont Cont
Tel Tel
A
C
B
D
0
5
10
15
20
0
1
2
3
4
5
6
R
e
l
a
t
i
v
e
 
E
x
p
r
e
s
s
i
o
n
O
f
 
P
6
3
 
P
r
o
t
e
i
n
R
e
l
a
t
i
v
e
 
E
x
p
r
e
s
s
i
o
n
O
f
 
T
R
A
I
L
 
P
r
o
t
e
i
n
Cont
Cont
Tel
TelMolecular Cancer 2005, 4:24 http://www.molecular-cancer.com/content/4/1/24
Page 10 of 14
(page number not for citation purposes)
majority of chromosomes and growth arrest of the cancer
cells without affecting the normal cells from stomach and
intestine; 2) induction of both senescence and apoptosis;
and 3) up-regulation of key regulatory genes involved in
cell cycle arrest and apoptosis.
RNA interference has emerged as a method for effective
and specific inhibition of gene expression both in vitro
and in vivo [18,25]. This study shows that a mixture of siR-
NAs directed against two different regions of telomerase
produced near complete silencing of telomerase function
along with suppression of the protein. The mixture of siR-
NAs in nanomolar concentration led to 77 ± 3% inhibi-
tion of telomerase activity within 24 hours and near
complete inhibition in 72 hours.
Inhibition of telomerase activity was associated with a
marked reduction (30% of the control) in median tel-
omere length. The effect of RNAi-mediated inhibition of
telomerase activity on telomere length has not been
reported before. However, other inhibitors of telomerase
have been shown to produce similar median reduction in
telomere length. The estimation of median telomere
length, however, does not provide information on
telomere length on individual chromosomes that possess
telomere of different lengths. Loss of all telomeres in a
small number of chromosomes may trigger a DNA dam-
age response when median telomere length is not criti-
cally reduced. In order to determine loss of telomeres on
individual chromosomes, we hybridized metaphase chro-
mosome spreads of treated and untreated cells with Cy3-
PNA (C3TA2)3 probe. We found that in siRNA treated cells,
60% of chromosomes had no telomere signal, indicating
complete erosion of telomeres on these chromosomes.
These data suggest that the siRNAs produced potent inhi-
bition of telomerase activity and loss of telomeres on
majority of the chromosomes.
SiRNA mediated telomerase inhibition also resulted in
cell death of >80% cancer cells in four weeks. The long
delay of four weeks that was required for induction of cell
death is consistent with the fact that loss of telomerase
caused a relatively gradual telomere shortening. A tel-
omere length below critical ~2 kbp [19], has been
reported to result in growth arrest [20]. The growth arrest
was associated with replicative senescence and apoptosis.
Telomere shortening induces senescence [21] which is
permanent and irreversible cell cycle arrest in G1 phase
thereby halting growth. Senescent cells express β-galactos-
idase and develop a characteristic flat and vacuole-rich
cytoplasmic morphology, but remain metabolically active
and are eliminated by cell necrosis and phagocytosis [22].
However, more recently senescent cells have been shown
also to undergo p73 mediated apoptotic cell death in can-
cer cells. Telomerase inhibitors have been reported to
cause replicative senescence in cancer cells [6]. Telomerase
gene suppression by siRNAs induced β-galactosidase
expression in 41 ± 6% and typical senescent phenotype in
a subset (10 ± 4%) of the cells.
Telomerase inhibition with the siRNA mixture also
induced apoptosis in 86 ± 5% of the cancer cells. Apopto-
sis was confirmed by both the annexin V labeling and
PARP cleavage. Since molecular suppression of telomer-
ase by gene silencing using siRNA is highly selective, these
studies show that apoptosis is specifically due to telomer-
ase inhibition. Although, chemical inhibitors of telomer-
ase have also been reported to cause apoptosis [7], it was
not clear whether they produced apoptosis specifically
due to telomerase suppression or due to their unrelated
side effects. However, induction of both senescence and
apoptosis has also been observed following specific inhi-
bition of telomerase by oligo-nucleotides targeting RNA
component of telomerase.6 It has been suggested that tel-
omerase inhibitors may cause apoptosis due to severe and
precipitous telomere shortening that may be associated
with chromosomal rearrangement and DNA fusion. This
condition termed 'crisis' may be associated with activation
of apoptotic pathways resulting in apoptotic cell death of
the cancer cells.
Signaling pathway of telomere shortening-induced repli-
cative senescence and apoptosis in the cancer cells is not
fully understood. Telomere shortening may be recognized
as DNA damage. This is supported by the fact that in the
adenocarcinoma SEG 1 cells, telomerase inhibition was
associated with over expression of gene for HR 23B, an
early marker of DNA damage [23].
Telomerase suppression and telomere shortening was also
associated with up-regulation of genes for p73, p63 of the
p53 gene family. Expression of p63 was also confirmed by
western blot analysis. Although P53 is frequently mutated
in cancer, p73 and p63 are rarely affected. Unlike p53, p73
and p63 exist in different isoforms that may have different
targets and opposing effects on replicative senescence and
apoptosis. For example, whereas full length form called
p73α may induce cell cycle arrest and apoptosis, its trun-
cated isoform AN-p73 actually inhibits cell cycle arrest
and apotosis. p73 and p63, like p53, remain localized to
the cell nucleus and exert their effects by regulating expres-
sion of other genes such as those that mediate cell cycle
arrest and apoptosis. Although the precise regulation of
p53 family members is not fully understood, it is clear
that expressions of p53, p73 and p63 are differently regu-
lated. P73 and p63 share many but not all target genes
with p53. Furthermore, the genetic alterations associated
with DNA damage are complex and involve genes other
than those in the p53 family only that may also influenceMolecular Cancer 2005, 4:24 http://www.molecular-cancer.com/content/4/1/24
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replicative senescence and apoptosis. For example, E2F1
may induce apoptosis through p53-independent mecha-
nisms. These studies suggest that inhibition of telomerase
causes loss of telomeres; loss of telomeres is sensed as
DNA damaged by DNA damage sensor such as HR23B;
this through other intermediary proteins may lead to up-
regulation of p73, p63, E2F1, and mdm2 (see Additional
file 1). It has also been shown that in response to DNA
damage, E2F1 is stabilized which subsequently upregu-
lates p73. Similarly mdm2 which binds with p53 to
inhibit its activity, infact positively regulates p63 and
probably also p73.
Up-regulation of p73, p63 and E2F1 may mediate replica-
tive senescence. Cyclin dependent kinase inhibitor, p21 is
a key mediator of cell cycle arrest and is a target for p53.
Senescence associated with telomere shortening during
ageing is accompanied by p53 mediated p21 upregula-
tion. However, p73, p63 and E2F1 have also been shown
to cause p53 independent up-regulation of p21. There-
fore, it appears that telomerase suppression in SEG- 1 can-
cer cells leads to induction of p73, p63 and E2F1, which
may up-regulate p21 leading to cell cycle arrest and senes-
cence. In addition p16 and GAAD45 were also
upregulated in the telomerase siRNA treated cells. Both
p16 and GAAD45 are potent inhibitors of cell cycle and
contribute to replicative senescence in the cancer cells
In our studies telomerase suppression in SEG1 cells was
also associated with up-regulation of genes for FasL, Fas
and caspase 8, suggesting that in these cells telomere
shortening leads to activation of death receptor mediated
apoptosis. P73 can upregulate several genes whose prod-
ucts participate in mitochondrial apoptotic pathway. We
found upregulation of caspase recruitment domain con-
taining protein 9 (CARD9) that has been implicated in
apoptosis through interaction with Bcl10 and activation
of NFKB [24]. We also found that there was upregulation
of genes for caspase7 and caspase 3 which are executioner
caspases that are implicated in the cleavage of PARP in the
final stages of apoptosis. Consistent with these data, a
marked induction in the appearance of cleaved (89 kDa)
PARP fragment (Figure 5B) was seen in telomerase siRNA
treated adenocarcinoma cells. Western blot analysis also
indicated a substantial upregulation of TRAIL, which
induces apoptosis in cancer cells but not in normal cells.
The gene expression studies provide only an overview of
changes in genes involved in the apoptotic pathways.
Although for p63, FASL, and p16, the expression changes
were confirmed by western blot analyses, further studies
of changes in protein expression and activities would be
required to fully define the signaling pathways.
In contrast to the effect on the cancer cells, telomerase
inhibition did not affect normal somatic cells. This may
be due to the fact that normal somatic cells do not express
telomerase. Moreover, signaling pathway for these
responses in the cancer cells involve p53 homologs p73a,
p63a and others that are different from p53-mediated
responses in normal cells. Further studies in telomerase
expressing normal cells are needed to determine whether
effects of the telomerase siRNA are selective for cancer
cells.
Conclusion
Replicative senescence and apoptosis constitute the "fail-
safe" mechanism against cancer development and devel-
opment of resistance to replicative senescence and
apoptosis is "life line" of cancer cells [1]. Disruption of
these pathways is a major goal of chemoprevention, treat-
ment, prevention of recurrences and overcoming resist-
ance to chemotherapy in cancers. By selectively inducing
both cell cycle arrest and apoptosis in cancer cells but not
in normal somatic cells, Inhibitors of telomerase hold
great promise as 'safe' anti-cancer therapeutic agents.
SiRNA strategy against telomerase may provide a highly
effective and selective method of telomerase inhibition.
SiRNAs have been shown to be suitable for in vivo delivery
and utilization [18]. Further studies, however, are needed
to investigate the value of telomerase siRNA in chemopre-
vention and treatment of Barrett's associated
adenocarcinoma.
Methods
Cell lines
Esophageal adenocarcinoma cell line (SEG-1), derived
from Barrett's's-associated adenocarcinoma of the distal
esophagus, was obtained from Dr. David Beer, University
of Michigan, Ann Arbor, MI. Normal cell strain from
stomach and intestine (CRL7869) was purchased from
American Type Culture ollection (Rockville, MD).
SiRNAs
We designed two siRNA duplexes targeting two different
regions of the telomerase gene according to Harborth's
criteria [25] for choosing sequences and making siRNA
duplexes for target mRNAs. SiRNAs with sense-strand
sequences 5'-AAATGCGGCCCCTGTTTCTGG-3' (HTERT
A) and 5'-AACATGCGTCGCAAACTCTTT-3' (HTERT B)
were submitted in a BLAST search of human EST libraries
to ensure that other human genes were not targeted. Pre-
annealed siRNA duplexes of above sequences were pur-
chased from Dharmacon Research (Lafayette, CO, USA).
For optimization of siRNA transfection, different concen-
trations of Cy-3 labeled control RNA duplexes (Dhar-
macon) were delivered into cells using effectene (Qiagen
Inc., Valencia, CA), superfact (Qiagen), TransIT-TKO
Transfection Reagent (Mirus, Madison, WI), as describedMolecular Cancer 2005, 4:24 http://www.molecular-cancer.com/content/4/1/24
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by the manufacturer or by eectroporation, as reported by
us previously [11].
SiRNA transfection
The cells were maintained in monolayer culture at 37°C
in humidified air with 5% CO2 in Dulbecco's Modified
Eagle Medium (DMEM) (Sigma chemical, St. Louis, MO)
containing 10% fetal bovine serum, as desribed previ-
ously [7,11,26]. For optimization of siRNA transfection,
different transfection procedures and siRNA concentra-
tions were used to deliver Cy3-labeled control siRNAs into
SEG-1 cells. Transfection using TKO Transfection Reagent
(Mirus, Madison, WI) and 50 nM siRNA gave the best
transfection efficiency and therefore was used in subse-
quent experiments to study the effect of telomerase siR-
NAs on telomere length and survival of BEAC cells.
Normal (CRL7869) and adenocarcinoma (SEG-1) cells
were transfected with mixture of both telomerase specific
siRNAs (Tel-siRNAs). Cells transfected with chemically
unmodified non-targeting siCONTROL siRNA (Cont-
siRNA) served as a control for non-sequence-specific
effects of these molecules.
Immunocytochemical detection of telomerase
The cells were evaluated for telomerase expression at day
7 following transfection. Cytospins of cells transfected
with control or telomerase siRNAs were fixed in metha-
nol/acetone (1:1, v/v) for 10 min at -20°C. Fixed cells
were rinsed, rehydrated in PBS, and incubated for 2 h at
RT with rabbit polyclonal antibody to telomerase (Novus
Biologicals, Inc., Littleton, CO). Antigen-antibody com-
plex was detected by incubation with a fluorescein isothi-
ocyanate (FITC)-labeled secondary antibody.
Western Blotting
Approximately 50 mg of protein was suspended in Lae-
mmli's sample buffer (0.1 M Tris-HCl buffer pH 6.8, 1%
SDS, 0.05% β-mercaptoethanol, 10% glycerol, and
0.001% bromphenol blue), boiled for 2 minutes, and
electrophoresed on 4–20% glycerol gradient SDS-acryla-
mide gel for 4 h at 120 V. Gels were electroblotted onto
Trans-Blot nitrocellulose membrane (membrane; Bio-Rad
Laboratories, Hercules, CA) at 40 V for 3 h in a Tris-glycine
buffer system. Incubation with indicated antibodies was
performed for 2 h in PBS-Tween 20 (PBST) containing 1%
BSA with constant rocking. Blots were washed with PBST
and incubated in either anti-rabbit or anti-mouse horse-
radish peroxidase (HRPO) conjugates for 2 h in PBST con-
taining 3% nonfat dry milk. After washing, specific
proteins were detected using an enhanced
chemiluminescence, according to the instructions pro-
vided in the manual (Amersham Life Sciences Inc., Arling-
ton Heights, IL).
Assay of telomerase activity
Telomerase activity was assayed using a fluorescence-
based TRAPEZER XL telomerase detection kit (Intergen,
Purchase, NY). TRAPEZER XL telomerase detection kit pro-
vides a refined and fluorometric version of the original
TRAP (Telomeric Repeat Amplification Protocol) assay.
The kit utilizes "Fluorescence Energy Transfer" primers to
generate fluorescently labeled TRAP products and thus
allows a highly sensitive and quantitative non-isotopic
detection of telomerase activity in vitro. Lysates (1000 cell-
equivalents) are mixed with TRAPEZER XL reaction mix
containing Amplifuor™ primers, and incubated at 30°C
for 30 minutes. Amplified telomerase products are
quantitated with a fluorescence plate reader. Telomerase
activity (in TPG units) is calculated by comparing the ratio
of telomerase products to an internal standard for each
lysate, as described by the manufacturer.
Growth kinetics
SEG-1 cells (5 × 105 per dish) were transfected with con-
trol or telomerase-specific siRNAs, as described above.
The transfected cells were harvested by trypsinization,
counted and replated weekly at the same live cell number.
Prior to re-plating, portions of cells were removed for
telomere length, gene expression, and apoptosis/senes-
cence assays.
Estimation of telomere length
Gel-based analysis
For gel-based ananysis of median telomere length,
genomic DNA was isolated from telomestatin-treated cells
using "Puregene" DNA isolation kits (Gentra Systems,
Minneapolis, MN) and telomere length was estimated uti-
lizing the "TeloTAGGG Telomere Length Assay" (Roche
Diagnostics Corporation, Roche Applied Science, Indian-
apolis, IN). In brief, 6 µg of genomic DNA was digested
with a sixfold excess of restriction enzymes HinfI and RsaI.
Digested DNA, along with a size standard (1-kb DNA lad-
der), was electrophoresed on 0.8% agarose gel and trans-
ferred to Hybond-N+ nylon membrane (Amersham
Biosciences Corp, Piscataway, NJ) as described by the
manufacturer. Membranes were then hybridized to a dig-
oxigenin (DIG)-labeled telomere-specific probe and telo-
meric DNA was detected by incubation with alkaline
phosphatase coupled to anti-DIG antibody, followed by
washing and reaction with a chromogenic substrate of
alkaline phosphatase.
Telomere-FISH
Cells were treated with KaryoMax (Gibco), hypotonic
solution and fixed in glacial acetic acid – ethanol (1:3).
For the direct comparison of samples, cell suspensions in
the fixative were droped onto a single slide using the 8-
well applicator (the plastic top of CultureSlide, Becton
Dickinson Labware, Bedford, MA), dropping each sampleMolecular Cancer 2005, 4:24 http://www.molecular-cancer.com/content/4/1/24
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to the designated well. The air-dried specimens were than
processed under virtually identical hybridization condi-
tions, under one coverslip. Q-FISH was done using the
Cy3-PNA (C3TA2)3 probe (Applied Biosystems/ Boston-
Probes, Bedford, MA) as described by Lansdorp [27].
Images were acquired using a 60×/1.40 PlanApo Nikon
objective, Nikon Eclipse E6000 microscope equipped
with the SD-300-V Optical Head, and Spectral Acquisition
v.2.0 software (Applied Spectral Imageing, Vista, CA).
Eighty nuclei were analyzed per each sample. The length
of a telomere is directly related to its integrated fluores-
cence intensity value. The quantification of probe signals
was done by FISHView v.2.1.1 software (Applied Spectral
Imageing) according to manufacturers'
recommendations.
Senescence Assay
Cells were rinsed three times with PBS and fixed in 2%
formaldehyde and 0.2% glutaraldehyde solution in in
PBS. The cells were washed again as described above and
stained overnight in solution containing 1 mg/ml X-gal,
40 mM citric acid/sodium phosphate (pH 6), 5 mM potas-
sium ferrocyanide, 150 mM NaCl, and 2 mM MgCl2 [28].
Next day, the stain was removed, cells were rinsed with
PBS and staining was viewed under an Olympus® fluores-
cence microscope.
Apoptosis Assay
Apoptotic cells were detected using an Annexin V-Biotin
Apoptosis Detection Kit (Oncogene Research Products,
San Diego, CA). SiRNA-treated myeloma cells (1 × 106
cells per ml) were mixed with annexin V-biotin and media
binding reagent and incubated in the dark for 15 min at
room temperature (RT). Cells were then centrifuged and
medium was replaced with 1 × Binding Buffer (Oncogene
Research Products, San Diego, CA) containing fluorescein
isothiocyanate(FITC)-streptavidin (Amersham). Propid-
ium iodide (PI) was added to discriminate early apoptotic
cells from late apoptotic or necrotic cells. A portion of cell
suspension (50 µl) was placed onto a glass slide, covered
with a cover slip and viewed immediately using a fluores-
cence microscope equipped with FITC (green) and PI
(red) filters. Two hundred cells, representing at least five
distinct microscopic fields, were analyzed to assess the
fraction of FITC and PI-labeled cells for each sample.
Gene Expression Analysis
Total RNA was isolated utilizing an "RNeasy" kit (Qiagen
Inc., USA) and gene expression profile was evaluated
using HG-U133 array (Affymetrix, Santa Clara, CA) repre-
senting ~33,000 human genes as described previously [7].
GeneChip® arrays were scanned on a GeneArray® Scanner
(Affymetrix, Inc., Santa Clara, CA). Array normalization,
expression value calculation and clustering analysis were
performed using the dChip Analyzer. The Invariant Set
Normalization method was used to normalize arrays at
probe level to make them comparable, and the model-
based method was used for probe selection and to com-
pute expression values [29,30]. These expression levels
were assigned standard errors based on replicates, which
were subsequently used to compute 90% confidence
intervals of fold changes in inter-group comparisons. The
lower confidence bounds of "fold change" were conserva-
tive estimates of the actual changes. Expression of key
genes involved in DNA damage sensing, repair, cell cycle
arrest and apoptosis was analyzed.
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